Your browser doesn't support javascript.
loading
Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study.
Wang, Xia; Minhas, Jatinder S; Moullaali, Tom J; Di Tanna, Gian Luca; Lindley, Richard I; Chen, Xiaoying; Arima, Hisatomi; Chen, Guofang; Delcourt, Candice; Bath, Philip M; Broderick, Joseph P; Demchuk, Andrew M; Donnan, Geoffrey A; Durham, Alice C; Lavados, Pablo M; Lee, Tsong-Hai; Levi, Christopher; Martins, Sheila O; Olavarria, Veronica V; Pandian, Jeyaraj D; Parsons, Mark W; Pontes-Neto, Octavio M; Ricci, Stefano; Sato, Shoichiro; Sharma, Vijay K; Silva, Federico; Thang, Nguyen H; Wang, Ji-Guang; Woodward, Mark; Chalmers, John; Song, Lili; Anderson, Craig S; Robinson, Thompson G.
Afiliação
  • Wang X; The George Institute for Global Health, University of New South Wales, Australia (X.W., T.J.M., G.L.D.T., X.C., H.A., C.D., M.W., J.C., L.S., C.S.A).
  • Minhas JS; Department of Cardiovascular Sciences (J.S.M., T.G.R.), University of Leicester, United Kingdom.
  • Moullaali TJ; National Institute for Health Research Leicester Biomedical Research Centre, United Kingdom (J.S.M., T.G.R.).
  • Di Tanna GL; The George Institute for Global Health, University of New South Wales, Australia (X.W., T.J.M., G.L.D.T., X.C., H.A., C.D., M.W., J.C., L.S., C.S.A).
  • Lindley RI; Centre for Clinical Brain Sciences, University of Edinburgh, United Kingdom (T.J.M.).
  • Chen X; The George Institute for Global Health, University of New South Wales, Australia (X.W., T.J.M., G.L.D.T., X.C., H.A., C.D., M.W., J.C., L.S., C.S.A).
  • Arima H; Westmead Applied Research Centre (R.I.L.), University of Sydney, NSW, Australia.
  • Chen G; The George Institute for Global Health, University of New South Wales, Australia (X.W., T.J.M., G.L.D.T., X.C., H.A., C.D., M.W., J.C., L.S., C.S.A).
  • Delcourt C; The George Institute for Global Health, University of New South Wales, Australia (X.W., T.J.M., G.L.D.T., X.C., H.A., C.D., M.W., J.C., L.S., C.S.A).
  • Bath PM; Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Japan (H.A.).
  • Broderick JP; Department of Neurology, Xuzhou Central Hospital, China (G.C.).
  • Demchuk AM; The George Institute for Global Health, University of New South Wales, Australia (X.W., T.J.M., G.L.D.T., X.C., H.A., C.D., M.W., J.C., L.S., C.S.A).
  • Donnan GA; Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, Macquarie Park, New South Wales, Australia (C.D.).
  • Durham AC; Stroke Trials Unit, School of Medicine, University of Nottingham, United Kingdom (P.M.B.).
  • Lavados PM; Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute, University of Cincinnati, OH (J.P.B.).
  • Lee TH; Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Canada (A.M.D.).
  • Levi C; Melbourne Brain Centre, Royal Melbourne Hospital (G.A.D.), University of Melbourne, Victoria, Australia.
  • Martins SO; Department of Cardiovascular Sciences (J.S.M., T.G.R.), University of Leicester, United Kingdom.
  • Olavarria VV; Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Clinica Alemana Universidad del Desarrollo School of Medicine, Santiago, Chile (P.M.L., V.V.O.).
  • Pandian JD; Stroke Center and Department of Neurology, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.).
  • Parsons MW; University of Newcastle, School of Medicine and Public Health, University Drive, Callaghan, NSW, Australia (C.L.).
  • Pontes-Neto OM; Hunter Medical Research Institute, New Lambton Heights, Australia (C.L.).
  • Ricci S; The Sydney Partnership for Health, Education, Research and Enterprise, Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia (C.L.).
  • Sato S; Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Porto Alegre, Brazil (S.O.M.).
  • Sharma VK; Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Clinica Alemana Universidad del Desarrollo School of Medicine, Santiago, Chile (P.M.L., V.V.O.).
  • Silva F; Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.).
  • Thang NH; Neurology Department, Royal Melbourne Hospital (M.W.P.), University of Melbourne, Victoria, Australia.
  • Wang JG; Department of Neurosciences and Behavioral Sciences, University of Sao Paulo, Ribeirao Preto Medical School, Brazil (O.M.P.-N.).
  • Woodward M; Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.).
  • Chalmers J; Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.).
  • Song L; Yong Loo Lin School of Medicine, National University of Singapore and Division of Neurology, National University Hospital (V.K.S.).
  • Anderson CS; Neurovascular Sciences Group, Neurological Institute, Hospital Internacional de Colombia, Bucaramanga (F.S.).
  • Robinson TG; Department of Cerebrovascular Disease, The People 115 Hospital, Ho Chi Min, Vietnam (N.H.T.).
Stroke ; 53(3): 779-787, 2022 03.
Article em En | MEDLINE | ID: mdl-34702064
ABSTRACT
BACKGROUND AND

PURPOSE:

In thrombolysis-eligible patients with acute ischemic stroke, there is uncertainty over the most appropriate systolic blood pressure (SBP) lowering profile that provides an optimal balance of potential benefit (functional recovery) and harm (intracranial hemorrhage). We aimed to determine relationships of SBP parameters and outcomes in thrombolyzed acute ischemic stroke patients.

METHODS:

Post hoc analyzes of the ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study), a partial-factorial trial of thrombolysis-eligible and treated acute ischemic stroke patients with high SBP (150-180 mm Hg) assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) alteplase and intensive (target SBP, 130-140 mm Hg) or guideline-recommended (target SBP <180 mm Hg) treatment. All patients were followed up for functional status and serious adverse events to 90 days. Logistic regression models were used to analyze 3 SBP summary measures postrandomization attained (mean), variability (SD) in 1-24 hours, and magnitude of reduction in 1 hour. The primary outcome was a favorable shift on the modified Rankin Scale. The key safety outcome was any intracranial hemorrhage.

RESULTS:

Among 4511 included participants (mean age 67 years, 38% female, 65% Asian) lower attained SBP and smaller SBP variability were associated with favorable shift on the modified Rankin Scale (per 10 mm Hg increase odds ratio, 0.76 [95% CI, 0.71-0.82]; P<0.001 and 0.86 [95% CI, 0.76-0.98]; P=0.025) respectively, but not for magnitude of SBP reduction (0.98, [0.93-1.04]; P=0.564). Odds of intracranial hemorrhage was associated with higher attained SBP and greater SBP variability (1.18 [1.06-1.31]; P=0.002 and 1.34 [1.11-1.62]; P=0.002) but not with magnitude of SBP reduction (1.05 [0.98-1.14]; P=0.184).

CONCLUSIONS:

Attaining early and consistent low levels in SBP <140 mm Hg, even as low as 110 to 120 mm Hg, over 24 hours is associated with better outcomes in thrombolyzed acute ischemic stroke patients. Registration URL https//www.clinicaltrials.gov; Unique identifier NCT01422616.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pressão Sanguínea / Terapia Trombolítica / Ativador de Plasminogênio Tecidual / AVC Isquêmico / Hipertensão Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pressão Sanguínea / Terapia Trombolítica / Ativador de Plasminogênio Tecidual / AVC Isquêmico / Hipertensão Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article